Raymond James Trust N.A. Has $441,000 Position in Regeneron Pharmaceuticals, Inc. (REGN)

Raymond James Trust N.A. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 899 shares of the biopharmaceutical company’s stock after purchasing an additional 71 shares during the quarter. Raymond James Trust N.A.’s holdings in Regeneron Pharmaceuticals were worth $441,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Sterling Investment Advisors Ltd. raised its stake in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 28 shares during the last quarter. FNY Partners Fund LP raised its stake in Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 200 shares during the last quarter. FNY Managed Accounts LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $140,000. Alpha Windward LLC raised its stake in Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1 shares during the last quarter. Finally, IFP Advisors Inc raised its stake in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 96 shares during the last quarter. 67.96% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at 433.45 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $325.35 and a 12-month high of $543.55. The stock has a market cap of $45.96 billion, a PE ratio of 43.48 and a beta of 1.65. The firm has a 50-day moving average price of $472.80 and a 200-day moving average price of $445.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same period last year, the business earned $2.82 EPS. The firm’s revenue was up 21.2% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.90 EPS for the current fiscal year.

In related news, major shareholder Sanofi acquired 166,415 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average cost of $480.93 per share, with a total value of $80,033,965.95. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the transaction, the chief financial officer now directly owns 10,099 shares in the company, valued at $5,060,204.94. The disclosure for this sale can be found here. Insiders sold a total of 99,543 shares of company stock worth $47,831,369 over the last three months. 10.40% of the stock is owned by company insiders.

Several research analysts recently weighed in on the stock. J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 15th. Robert W. Baird downgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price for the company. in a research note on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $472.00 target price (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 target price for the company in a research note on Wednesday, August 9th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $580.00 price objective (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $491.43.

COPYRIGHT VIOLATION NOTICE: “Raymond James Trust N.A. Has $441,000 Position in Regeneron Pharmaceuticals, Inc. (REGN)” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/09/17/raymond-james-trust-n-a-has-441000-position-in-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply